Molecular Diagnostics for Pharmacogenetic Testing: Testing volume, cost per test, and market potential

SCOPE AND METHODOLOGY

MARKET CONTEXT

• Exhibit 1: Distribution of Molecular Diagnostics Testing in U.S. 2004

PHARMACOGENETICS: TARGETS AND TRENDS
PRODUCTS AND PROGRESS OF NOTE
NUMBER OF TESTS

• Exhibit 2: Projected Pharmacogenetic Testing by Molecular Diagnostics in U.S. 2003-2013
• Exhibit 3: Trending in Projected Number of Pharmacogenetic Tests by Molecular Diagnostics in U.S. 2003-2013
• Exhibit 4: Trending in Percentage Distribution of Pharmacogenetic Tests by Molecular Diagnostics in U.S. 2003-2013

MARKET AND COST PER TEST PROJECTIONS, 2003-2013

• Exhibit 5: Projected Molecular Diagnostics Pharmacogenetic Testing Market Potential in U.S. 2003-2013
• Exhibit 6: Trending in Projected Test Volume for Molecular Diagnostics in Pharmacogenetic Testing in U.S. 2003-2013
• Exhibit 7: Trending in Projected Test Volume Composition for Molecular Diagnostics in Pharmacogenetic Testing in U.S. 2003-2013
• Exhibit 8: Trending in Projected Market Potential for Molecular Diagnostics inPharmacogenetic Testing in U.S. 2003-2013
• Exhibit 9: Trending in Projected Market Potential Composition for Molecular Diagnostics in Pharmacogenetic Testing in U.S. 2003-2013
• Exhibit 10: Trending in Projected Average Cost per Test for Molecular Diagnostics in Pharmacogenetic Testing in U.S. 2003-2013

MAJOR COMPETITORS

• Affymetrix, Inc.
• Celera Genomics/Celera Diagnostics (Division of Applera Corporation)
• Cepheid, Inc.
• Chiron Corporation
• Gene Logic, Inc.
• Gen-Probe Incorporated
• Myriad Genetics, Inc.
• Nanogen, Inc.
• Orchid BioSciences, Inc.
• Roche Diagnostics Division/Roche Molecular Systems
• F. Hoffmann-LaRoche Ltd.